Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.
On February 7, the NIH announced that it would begin capping indirect cost payments for new and existing research grants at 15%.
The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic atrophy secondary to AMD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback